Articles
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Perinatal and postnatal exposures and risk of young-onset breast cancer
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
No hay comentarios:
Publicar un comentario